FDA Approved AQNEURSA Ushers In New Hope For Niemann-Pick Disease Type C Patients
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine), the…
Articles
Will Vimseltinib Be the Miracle Cure TGCT Patients Have Prayed For?
In the world of rare disease therapeutics, Vimseltinib has emerged as a groundbreaking oral kinase inhibitor. This…
Is Grafapex Worth It in 2025? Pros, Cons, and Clinical Trial
In January 2025, the FDA approved Grafapex™ (treosulfan) in combination with fludarabine as a conditioning…
Gomekli (Mirdametinib): Hope for Inoperable NF1 Cases
Gomekli™ (mirdametinib) has emerged as a significant advancement in the treatment of neurofibromatosis type 1…
Is Alyftrek Drug Heralding a New Era in Cystic Fibrosis Treatment?
The Alyftrek drug, a groundbreaking once-daily triple-combination therapy, received U.S. Food and Drug Administration (FDA) approval…
Datroway: 37% Reduction In The Risk Of Death VS Chemotherapy
Based on the TROPION-Breast01 trial, Daiichi Sankyo and AstraZeneca’s DATROWAY was approved for the first…
6 Must-Know Facts About Briviact for Partial-Onset Seizures
Epilepsy is a chronic neurological disorder that affects an estimated 65 million people worldwide. Briviact…
Akynzeo Capsule | One Capsule, Dual Protection
Akynzeo capsule is an FDA-approved antiemetic medication specifically designed to address both acute and delayed…
Discover Briumvi Uses, Dosage, and Side Effects
NEW YORK, April 8, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.(TGTX) announced today that it…
Cobenfy: A New Frontier In Schizophrenia Treatment Faces Early Challenges
In September 2024, the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium…